



Consensus Business Group (“CBG”) is a leading UK-based investment group whose overall portfolio includes pharma, biotech, med-tech, cleantech, real estate and other business interests. It has a net asset value in excess of \$1.2 bn. CBG is also believed to be the largest owner and asset manager of residential freehold interests in the UK, representing in excess of 1% of the housing stock in England.

Vincent Tchenguiz, founder and Chairman of CBG, is a well-known property and financial investor with a track record as a financial innovator and expert in monetizing underlying value. His expertise, founded on years of foreign exchange trading and investing in the capital markets, led to the development of an arbitrage model securitizing property cashflows and the accumulation of a substantial property portfolio worth more than £4 billion pounds.

CBG’s investment approach is driven by deep analysis of worldwide trends and dynamics. Experts in structuring unique and strategic financial and business models, the group’s key areas of investments are in the healthtech, life science, climate change technologies and HLS sectors.

CBG has invested more than \$700m worldwide in several leading funds, incubators, holding companies and other direct investments. In Europe, CBG has been a long-time supporter of the Biogeneration Ventures and Forbion funds. Recent investments in the UK are in Mercia Asset Management and in leading University funds including Cambridge Innovation Capital. The global nature of CBG’s portfolio is reflected by its participation in an increasing number of US listings including Adicet, Biomx, Enlivex and Polypid.

CBG has a focus on investments in Israel where it has invested more than \$400m and continues to develop its strong ecosystem and partnerships with leading institutions and corporates. CBG’s strategic partners include leading hospital groups (including Hadassah University Hospital, Assuta Hospital and Medical Centers) and Health Maintenance Organisations (“HMOs”) (such as Maccabi), Universities, research centres, Governmental institutions, numerous incubators and innovation laboratories.

No representation or warranty (express or implied) is made regarding the accuracy or completeness of the information in this document. It does not constitute any form of advice or recommendation.

CBG is an LP or GP in multiple funds including Accelmed, Peregrine Ventures, Triventures, Capital Nature, Jerusalem Venture Partners (“JVP”), RMGP Biopharma Investment Fund, Pitango Venture Capital, Israel Biotech Fund (“IBF”), aMoon, ALIVE HealthTech Fund, Pontifax and others. CBG is also a leading shareholder and investor in holding companies and platforms, including Hadasit Bio Holdings (“HBL”), Xenia Venture Capital and the Trendlines Group. CBG has recently invested in Integra, the Hebrew University’s technology transfer company.

CBG investments also have a focus on technologies addressing climate change challenges, including those reducing carbon emissions and minimising the environmental impact of operations and products. Its cleantech ecosystem includes sectors such as energy, agritech, foodtech, AI, big data analytics and carbon tech solutions. Innovative solutions include investments in companies with technologies in everlasting solar batteries which provide energy for the lifetime of low-power devices. A number of CBG’s cleantech companies have their own TASE listing including Augwind, Bladeranger, Electreon, Trucknet and Chakratec.

CBG, together with the Israel Innovation Institute (NGO), has launched PLANETech, which, with the endorsement of Israel’s Minister for Environment and EU’s Ambassador to Israel, devotes its efforts to support climate change technologies and build a global network for climate tech innovators, investors, governments, and multinational corporations facing the challenge of decarbonising the global economy.

CBG’s advisory team supports its portfolio to ensure long-term success, including with its out-of-the-box-thinking, financial planning, managerial support, strategic development and channel to market strategy. CBG has developed and can assist its portfolio companies in developing a financial model for Climate Change, Biodiversity and the Planet., while also helping them to identify synergies across its wider portfolio and network. CBG also assists companies to pivot their technologies into technologies that also tackle climate change. CBG continues developing a financial model for Government to Government trading in healthcare and climate change technologies.

CBG is interested in working with other groups by introducing its portfolio companies, innovation centres and ecosystem to develop strategic partnerships or collaborations which will enable both entities to get exposure and access to their respective ecosystems and generate mutual benefits.